Give detailed medical review for this case with reference,in terms of clinical pharmacist
Reading File
Reading File
Running Command
Running Command
Running Command
Running Command
Finding Sources
Searching PubMed
"COPD" AND "acute exacerbation" AND "clinical pharmacist"
Finding Sources
Searching PubMed
"COPD" AND "acute exacerbation" AND "antibiotic" AND "treatment"
Searching PubMed
"unstable angina" AND "COPD" AND "pharmacotherapy"
Finding Sources
Searching PubMed
"COPD exacerbation" AND "ceftriaxone" AND "azithromycin"
Searching PubMed
"GOLD guidelines" AND "COPD" AND "pharmacotherapy"
Reading File
Reading File
Searching PubMed
"Klebsiella pneumoniae" AND "pneumonia" AND "antibiotic treatment"
Searching the Web
GOLD 2024 COPD guidelines acute exacerbation management pharmacotherapy clinical pharmacist review
Finding Sources
Finding Sources
Reading Web Page
COPD exacerbation pharmacist role antibiotic corticosteroid bronchodilator
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
I now have comprehensive data to write a detailed clinical pharmacist review. Let me compile it.
Clinical Pharmacist Review: Case of Mrs. KSN
Acute Exacerbation of COPD (AECOPD) with Bronchopneumonia and Unstable Angina
PATIENT SUMMARY
| Parameter | Details |
|---|---|
| Name | Mrs. KSN |
| Age/Sex | 73 years, Female |
| IP No. | 25051174 |
| Admission | 29/09/25 |
| Diagnoses | AECOPD (GOLD Group E) + Bronchopneumonia (Klebsiella pneumoniae) + Unstable Angina |
| PMH | Known COPD × 4 years |
1. SOAP ANALYSIS — CLINICAL PHARMACIST PERSPECTIVE
SUBJECTIVE
A 73-year-old female presents with a classic triad of AECOPD:
- Progressive breathlessness (5 days, exacerbated for 3 days)
- Productive cough with expectoration (3 days)
- Fever with chills (2 days, low-grade, insidious onset)
- Blood-tinged sputum (1 episode, morning)
- New onset chest pain on Day 3 (2 Oct) — resolved next day → consistent with unstable angina (demand ischemia in the setting of hypoxia, tachycardia, and increased myocardial oxygen demand)
OBJECTIVE
Vitals:
| Date | BP (mmHg) | Pulse (bpm) |
|---|---|---|
| 29/9 | 120/80 | 100 |
| 30/9 | 136/90 | 80 |
| 1/10 | 150/90 | 88 |
| 2/10 | 144/90 | 80 |
| 3/10 | 130/70 | 87 |
BP spike on Day 3 (150/90 mmHg) coincides with chest pain onset — likely hypertension-driven ischemia superimposed on COPD exacerbation.
CBC (Notable Findings):
| Parameter | Value | Reference | Interpretation |
|---|---|---|---|
| WBC | 8.71 × 10³/µL | 4–11 | Normal (atypical infection/viral?) |
| Lymphocytes | 44.8% | 20–40% | ↑ Elevated — suggests viral/atypical infection component |
| PCT (Plateletcrit) | 0.34% | 0.22–0.24% | ↑ Elevated — plaque activity, platelet aggregation |
| Platelets | 369 × 10³/µL | 150–410 | Normal |
| Hb | 13.0 g/dL | 12–15 | Normal |
| ESR | 17.6 mm/hr | <20 | Normal |
Serum Electrolytes: All within normal limits. K⁺ = 3.6 mEq/L (low-normal — relevant given diuretic risk and potassium supplementation at discharge).
Renal Function: Sr. Creatinine = 0.5 mg/dL — normal (no dose adjustments required).
Key Biomarkers:
| Test | Result | Reference | Interpretation |
|---|---|---|---|
| NT-proBNP | 286 pg/mL | <125 (normal); 200–400 (mild ↑) | Mildly elevated — early cardiac stress; no overt HF, but monitor |
| Troponin-I | 8.5 pg/mL | <16 pg/mL | Normal — rules out NSTEMI; supports unstable angina diagnosis |
| CRP | <5.0 mg/L | <1 normal; 1–10 mild ↑ | Mildly elevated — systemic inflammation |
| Sputum Culture | Klebsiella pneumoniae isolated | — | Gram-negative pathogen — guides antibiotic choice |
ASSESSMENT
1. AECOPD — GOLD Group E (Severe Exacerbation)
- Patient meets Anthonisen Criteria Type I: increase in dyspnea + sputum + fever → antibiotic indicated
- GOLD Group E = high exacerbation risk; requires escalation per GOLD 2024 guidelines
- Pathophysiology: inability to maintain alveolar ventilation due to increased intrinsic PEEP, high airway resistance, flattened diaphragm → respiratory muscle fatigue → rising PaCO₂ — Murray & Nadel's Textbook of Respiratory Medicine
2. Bronchopneumonia — Klebsiella pneumoniae
- Community-acquired Klebsiella pneumonia in a geriatric COPD patient — presents high morbidity risk
- Blood-tinged sputum ("currant-jelly sputum" of Klebsiella) is a classical warning sign in elderly patients
- CRP mildly elevated; lymphocytosis suggests possible mixed viral-bacterial etiology
3. Unstable Angina
- Troponin negative → non-NSTEMI
- NT-proBNP mildly elevated → early cardiac demand stress
- Elevated plateletcrit → platelet hyperactivity, elevated thrombotic risk
- Mechanism: COPD-induced hypoxia + tachycardia → increased myocardial O₂ demand → ischemia
2. DRUG THERAPY REVIEW (IN-HOSPITAL)
Inpatient Drug Chart Analysis
| Drug | Dose | Indication | Pharmacist Comments |
|---|---|---|---|
| Neb. Duolin (Levosalbutamol + Ipratropium) | 2.5 mL TID | AECOPD — bronchodilation | ✅ Appropriate. SABA + SAMA combination = first-line per GOLD 2024 & Washington Manual. Nebulization preferred in acute setting due to impaired MDI technique |
| Neb. Budecort (Budesonide 0.5 mg) | TID | Reduce airway inflammation | ✅ Appropriate. Inhaled corticosteroid via nebulizer. Counsel patient: rinse mouth after each nebulization to prevent oral candidiasis (Candida overgrowth) |
| Inj. Hydrocortisone | 100 mg | Systemic anti-inflammatory | ✅ Appropriate for severe AECOPD. Systemic corticosteroids improve hospital length of stay, lung function, and incidence of relapse. Should be switched to oral (prednisolone 40 mg/day × 5 days) early — Washington Manual of Medical Therapeutics |
| Inj. Cefera (Ceftriaxone 1.5 g) | Once daily | Klebsiella pneumonia | ✅ Appropriate. Ceftriaxone (3rd generation cephalosporin) covers gram-negative organisms including Klebsiella. Dose 1–2 g/day IV is standard; 1.5 g is acceptable — Goldman-Cecil Medicine |
| Tab. Azee (Azithromycin 500 mg) | Once daily | Atypical coverage; anti-inflammatory | ✅ Appropriate. Dual antibiotic for CAP + atypical coverage (lymphocytosis suggests Mycoplasma/viral co-infection). Azithromycin also has anti-inflammatory properties useful in AECOPD — Goldman-Cecil Medicine, GOLD 2024 pocket guide |
| Inj. Deriphyllin (Etophylline + Theophylline) | 1 amp | Bronchodilation | ⚠️ Caution. Methylxanthines carry serious risk of toxicity (narrow therapeutic index). Washington Manual states: "Owing to the risk of serious side effects, clinicians typically avoid using methylxanthines for acute exacerbations." Acceptable only if patient was previously on chronic theophylline — Washington Manual of Medical Therapeutics, p.321 |
| Inj. Pantoprazole | 40 mg | Gastroprotection (stress ulcer prophylaxis) | ✅ Appropriate. Recommended with systemic corticosteroids to prevent GI ulceration |
| Inj. Ondansetron (Emeset 4 mg) | PRN | Drug-induced nausea | ✅ Appropriate. Likely from Deriphyllin/azithromycin. Given from Day 2 onward appropriately |
| Tab. Calpol (Paracetamol 500 mg) | PRN | Fever | ✅ Appropriate. Safe in hepatically stable elderly patients |
| Tab. Anxit (Alprazolam 0.25 mg) | Day 1 only | Breathlessness-induced anxiety | ⚠️ Appropriate with caution. Benzodiazepines cause respiratory depression and should be used minimally in COPD. Correct decision to discontinue from Day 2 — monitor carefully |
| IVF NS 500 mL | 1 pint | Electrolyte maintenance | ✅ Appropriate — maintains hydration during acute illness |
3. DISCHARGE PRESCRIPTION REVIEW
| Drug | Dose/Duration | Purpose | Pharmacist Comments |
|---|---|---|---|
| Tab. Bactrim DS (TMP 160 mg + SMX 800 mg) | 1-0-1 × 5 days | Bacterial infection | ⚠️ Questionable. Bactrim is NOT a first-line drug for Klebsiella pneumonia (commonly resistant to TMP-SMX). Consider clinical justification — perhaps prophylaxis or sensitivity-guided. Per Washington Manual: TMP-SMX listed as alternative for uncomplicated AECOPD only, not Klebsiella pneumonia |
| Tab. Fluconazole (150 mg) | 1-0-1 × 5 days | Fungal prophylaxis | ✅ Appropriate. Prescribed to prevent oral/esophageal candidiasis secondary to corticosteroid + antibiotic use |
| Tab. Pan (Pantoprazole 40 mg) | 1-0-0 × 5 days | Gastroprotection | ✅ Appropriate continuation |
| Tab. Ecosprin Gold (Aspirin 75 mg + Clopidogrel 75 mg + Atorvastatin 40 mg) | 0-0-1 × 2 weeks | Unstable angina — antiplatelet + statin | ✅ Appropriate. Dual antiplatelet (aspirin + clopidogrel) is standard for unstable angina management. Atorvastatin stabilizes plaques and reduces CV events — Goldman-Cecil Medicine |
| Tab. Nikoran (Nicorandil 5 mg) | 1-0-0 × 5 days | Unstable angina — anti-anginal | ✅ Appropriate. Nicorandil acts via KATP channel activation + nitrate-like vasodilation → reduces pre/afterload. Has cardioprotective effects mimicking ischemic preconditioning. Note: Short t½ (~1 hr) — monitor for headache, GI ulceration, and avoid concurrent PDE5 inhibitors — Goodman & Gilman's, p.474–480 |
| Tab. Deriphyllin Retard (Etophylline + Theophylline 150 mg) | 1-0-1 × 2 weeks | Bronchodilation/pneumonia | ⚠️ Caution. Theophylline toxicity risk: nausea, cardiac arrhythmias, seizures. Narrow therapeutic index (5–15 mcg/mL). Serum theophylline levels should be monitored, especially in elderly patients. If continued, start at lowest dose, monitor carefully |
| Tab. Clonitril (Clonazepam 0.5 mg) | 0-0-1 × 5 days | Breathlessness/panic disorder | ⚠️ High risk in COPD. Benzodiazepines cause respiratory depression. Clonazepam is long-acting (t½ 18–50 hrs) — especially risky in elderly (Beers Criteria drug). At discharge, non-pharmacological approaches (pursed-lip breathing, yoga, mindfulness) are preferred. If necessary, use lowest dose with clear tapering plan |
| Syp. Potklor (KCl 10 mEq/5 mL) | 10 mL TID × 3 days | Potassium supplementation | ✅ Appropriate. K⁺ was low-normal (3.6 mEq/L). Corticosteroids and bronchodilators (beta-agonists) may cause hypokalemia. Replenishment is warranted |
4. DRUG-RELATED PROBLEMS (DRPs) — PHARMACIST IDENTIFICATION
| DRP | Description | Recommendation |
|---|---|---|
| Inappropriate antibiotic at discharge | Bactrim DS (TMP-SMX) for confirmed Klebsiella — Klebsiella often carries plasmid-mediated TMP-SMX resistance | Check culture sensitivity; consider switching to oral ciprofloxacin or amoxicillin-clavulanate if sensitive |
| Theophylline narrow TI | Deriphyllin used both IV (inpatient) and oral (discharge) without documented serum level monitoring | Monitor serum theophylline levels (target 5–15 mcg/mL); assess for toxicity symptoms (nausea, arrhythmia, tremors) |
| Benzodiazepine risk in COPD | Clonazepam at discharge — respiratory depressant, long-acting, Beers Criteria drug in elderly | Short course, lowest dose; reassess at Day 10 review; replace with non-pharmacological anxiolytics if possible |
| Ecosprin Gold dose discrepancy | Slide 12 counseling notes "Ecosprin Gold 20 mg" (atorvastatin 20 mg), while discharge table shows atorvastatin 40 mg | Clarify and reconcile the correct atorvastatin dose with prescriber |
| Nicorandil dose/frequency mismatch | Discharge: 5 mg once daily (1-0-0). Standard therapeutic dose is 10–20 mg BD. 5 mg once daily may be subtherapeutic given Nicorandil's short t½ of ~1 hr — Goodman & Gilman's | Review with cardiologist; consider 10 mg BD for adequate anti-anginal effect |
| BP management | Peak BP 150/90 on Day 3 — not separately addressed in drug therapy | Consider initiating antihypertensive if BP remains elevated at follow-up review |
| Corticosteroid hyperglycemia monitoring | Systemic hydrocortisone IV was used; no documented glucose monitoring | Monitor blood glucose; risk of steroid-induced hyperglycemia, especially in elderly |
| Drug Interaction: Azithromycin + Ondansetron | Both prolong QTc interval | Monitor ECG / QTc interval; avoid use together if QTc >450 ms |
5. PHARMACIST'S PLAN & MONITORING PARAMETERS
Monitoring Parameters
| Parameter | Target | Frequency |
|---|---|---|
| SpO₂ | ≥94% | Every 4–8 hrs during admission |
| Blood glucose | 80–180 mg/dL | Daily (steroid-induced hyperglycemia) |
| Serum potassium | 3.5–5.1 mEq/L | After potassium supplementation |
| Serum theophylline | 5–15 mcg/mL | 48–72 hrs after initiation |
| BP | <130/80 mmHg | Daily |
| Cardiac monitoring | Normal sinus rhythm | ECG if QTc concern (azithromycin + ondansetron) |
| Renal function | Creatinine stable | At 10-day follow-up |
| Sputum | Culture & sensitivity | As available |
6. PATIENT COUNSELING — PHARMACIST'S ADDITIONS
-
Inhaler technique: Demonstrate correct nebulizer technique. Explain each step of nebulizer care and assembly. After Budecort nebulization, always rinse mouth with water to prevent oral candidiasis.
-
Ecosprin Gold: Take at bedtime after food (to reduce GI irritation). Do not stop suddenly — antiplatelet withdrawal risk in unstable angina.
-
Nikoran (Nicorandil): May cause headache initially (nitrate-like effect) — reassure it resolves. Report any mouth/GI ulcers.
-
Deriphyllin Retard: Take with food. Report symptoms of toxicity: persistent nausea, heart palpitations, restlessness, fine tremors.
-
Clonitril (Clonazepam): Avoid driving. Do not combine with alcohol. This drug is for short-term use only — do not continue beyond 5 days without physician advice.
-
Bactrim DS: Take with plenty of water. Can cause skin rash — report immediately if rash, swelling, or breathing difficulty occurs (risk of SJS in susceptible individuals).
-
Breathlessness management: Teach pursed-lip breathing and tripod positioning (forward-lean with hands on knees) — reduces work of breathing during dyspneic episodes.
-
Smoking cessation: Primary COPD trigger. If patient or family members smoke — provide resources and counsel on cessation.
-
Vaccination: Recommend influenza vaccine annually and pneumococcal vaccine (PPSV23/PCV13) — the most impactful preventive interventions in COPD — US Pharmacist 2024 AECOPD review.
-
Follow-up review in 10 days: Check spirometry, re-evaluate cardiac status, reassess need for clonazepam and theophylline.
7. LIFESTYLE MODIFICATIONS (EVIDENCE-BASED)
Per GOLD 2025 and clinical evidence:
- Avoid dust, smoke, biomass combustion, chemical fumes (primary triggers)
- Pulmonary rehabilitation — can be started ≥4 weeks post-exacerbation. Reduces re-hospitalization risk
- Maintain healthy weight and hydration
- Practice pursed-lip breathing, yoga, meditation for breathlessness and anxiety control
- 100% medication adherence — particularly dual antiplatelet (Ecosprin Gold) and bronchodilators
- Use N95/surgical masks when in polluted or crowded environments
8. REFERENCES
- GOLD 2024/2025 Report — Global Initiative for Chronic Obstructive Lung Disease. GOLD 2024 Pocket Guide
- Goldman-Cecil Medicine, International Edition, 2-Volume Set (9780323930345) — Chapter 76: Treatment of COPD Exacerbations, p. 901
- Washington Manual of Medical Therapeutics (9781975190620) — Chapter 9: Pharmacotherapy for Acute Exacerbations of COPD, p. 320–321
- Murray & Nadel's Textbook of Respiratory Medicine, 2-Volume (9780323655873) — Chapter 136: Pathophysiology of COPD Exacerbation, p. 3193
- Goodman & Gilman's Pharmacological Basis of Therapeutics (9781264258079) — Nicorandil: Mechanism and Adverse Effects, pp. 474–480
- Harrison's Principles of Internal Medicine, 22nd Edition (9781265977061) — Nitrates in Unstable Angina, p. 473
- Katzung's Basic and Clinical Pharmacology, 16th Edition (9781260463309) — COPD Treatment including Methylxanthines, p. 2784
- Papke J, Loo C. "Overview of the Diagnosis and Treatment of COPD Exacerbations." US Pharmacist. 2024;49(8):34–40. Link
- Rosenwasser Y, Berger I, Loewy ZG. "Therapeutic Approaches for COPD Exacerbations." Pathogens. 2022 Dec. PMID: 36558847
- Anthonisen NR et al. "Antibiotic therapy in exacerbations of COPD." Ann Intern Med. 1987;106:196–204 — Original criteria for antibiotic indication in AECOPD
SUMMARY FOR CLINICAL PHARMACIST
This case presents a high-risk elderly female with GOLD Group E AECOPD complicated by confirmed Klebsiella pneumoniae bronchopneumonia and new unstable angina. Key pharmacist contributions include:
- Validating the use of SABA/SAMA nebulization and systemic corticosteroids as first-line AECOPD management
- Flagging the theophylline safety concern (narrow therapeutic index, toxicity risk in elderly)
- Questioning the appropriateness of TMP-SMX (Bactrim) for confirmed Klebsiella — culture sensitivity review is critical
- Identifying the QTc prolongation risk from simultaneous azithromycin + ondansetron
- Dose discrepancy in Ecosprin Gold (20 mg vs 40 mg atorvastatin) needing clarification
- Benzodiazepine stewardship — short-course clonazepam must be limited in COPD
- Nicorandil underdosing at 5 mg once daily vs. standard 10–20 mg BD
- Reinforcing medication adherence, inhaler technique, and vaccination as the most impactful pharmacist interventions per US Pharmacist 2024
This is a shared conversation. Sign in to Orris to start your own chat.